| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,435 | 1,785 | 20:40 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.08. | BPC Instruments AB (publ) reports results for H1 and Q2 2026 | 2 | Cision News | ||
| 10.06. | BPC INSTRUMENTS AB: BPC Instruments receives ISO 9001 certification for quality management | 1 | Cision News | ||
| 26.05. | Bulletin from the Annual General Meeting of BPC Instruments AB (publ) | 1 | Cision News | ||
| 19.05. | BPC Instruments AB: BPC Instruments partners with AURI on anaerobic digestion experimentation in the United States | 824 | PR Newswire | LUND, Sweden, May 19, 2026 /PRNewswire/ -- BPC Instruments AB (publ) ("BPC") has entered a strategic collaboration with the Agricultural Utilization Research Institute ("AURI") to improve... ► Artikel lesen | |
| 06.05. | BPC Instruments AB (publ) reports results for Q1 2026 | 2 | Cision News | ||
| BPC INSTRUMENTS Aktie jetzt für 0€ handeln | |||||
| 30.04. | BPC INSTRUMENTS AB: BPC Instruments discloses preliminary figures for the first quarter of 2026 | 1 | Cision News | ||
| 29.04. | BPC Instruments AB (publ) publishes Annual Report for 2025 | 1 | Cision News | ||
| 23.04. | Notice of Annual General Meeting in BPC Instruments AB (publ) | 1 | Cision News | ||
| 17.03. | BPC INSTRUMENTS AB: BPC Instruments launches BPC Connect - a smart hub for the BPC Go platform | 2 | Cision News | ||
| 26.02. | BPC Instruments AB: BPC Instruments reports results for 2025 | 487 | PR Newswire | LUND, Sweden, Feb. 26, 2026 /PRNewswire/ -- BPC Instruments AB (publ) hereby publishes the year-end report for the year 2025. The year-end report is available as... ► Artikel lesen | |
| 24.02. | BPC Instruments AB: BPC Instruments receives two repeat orders from Denmark within biogas applications | 876 | PR Newswire | LUND, Sweden, Feb. 24, 2026 /PRNewswire/ -- BPC Instruments AB (publ) has received two repeat orders from Denmark within biogas applications with a total value of approximately SEK 1.1 million.... ► Artikel lesen | |
| 19.02. | BPC Instruments AB: BPC Instruments secures order for BPC Blue system from global testing and certification group | 636 | PR Newswire | LUND, Sweden, Feb. 19, 2026 /PRNewswire/ -- BPC Instruments AB (publ) has received an order valued at approximately SEK 0.8 million for BPC's most advanced BPC Blue configuration, including... ► Artikel lesen | |
| 16.12.25 | BPC Instruments AB: BPC Instruments partners with SixRing to provide quality assurance for the EU and UK biomethane markets | 647 | PR Newswire | LUND, Sweden, Dec. 16, 2025 /PRNewswire/ -- BPC Instruments AB (publ) has entered into a collaboration with SixRing, the Canadian technology company behind Stimulose, a new feedstock additive... ► Artikel lesen | |
| 20.11.25 | BPC Instruments AB: BPC Instruments secures new order for several BPC Go units from a international energy group | 640 | PR Newswire | LUND, Sweden, Nov. 20, 2025 /PRNewswire/ -- BPC Instruments AB (publ) has received a new order valued at approximately SEK 0.9 million for several BPC Go units from a major international... ► Artikel lesen | |
| 12.11.25 | BPC Instruments AB: BPC Instruments reports results for the period January - September 2025 | 1.024 | PR Newswire | LUND, Sweden, Nov. 12, 2025 /PRNewswire/ -- BPC Instruments AB (publ) hereby publishes the interim report for the period January 1 - September 30, 2025. The interim report is available... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ERASCA | 16,035 | 0,00 % | FDA Fast Track Puts Erasca's (ERAS) Pancreatic Bet Center Stage | ||
| QIAGEN | 36,615 | -0,01 % | QIAGEN N.V. - 6-K, Report of foreign issuer | ||
| TANGO THERAPEUTICS | 23,360 | -2,75 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,050 | -5,94 % | Aktien New York Ausblick: Dow schwächelt weiter - Nasdaq stabil erwartet | NEW YORK (dpa-AFX) - Die US-Börsen steuern nach dem verlängerten Wochenende am Dienstag auf eine durchwachsene Eröffnung zu. Auf die Stimmung drückten die weiter steigenden Ölpreise, die der Angst... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,950 | -3,36 % | Mercks 30-Milliarden-Dollar-Blockbuster bekommt neue Konkurrenz - warum Big Pharma schon die nächste Plattform sucht | ||
| KYMERA THERAPEUTICS | 118,49 | +2,65 % | Kymera Therapeutics auf Citigroup-Gipfel: Offensive bei oralen Immunologie-Medikamenten gewinnt an Fahrt | ||
| BEAM THERAPEUTICS | 24,190 | -3,91 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| RELAY THERAPEUTICS | 19,040 | +1,98 % | Relay Therapeutics: Zovegalisib-Pipeline steht vor entscheidenden Meilensteinen | ||
| COGENT BIOSCIENCES | 33,620 | -1,55 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| VERA THERAPEUTICS | 33,520 | -0,77 % | Vera Therapeutics: Erfolgreicher Start für Nierenmedikament TRUTAKNA | ||
| TYRA BIOSCIENCES | 23,540 | +6,95 % | Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib | TYRA's mission is to make dabogratinib the clear first-line treatment choice for patients with LG IR NMIBC
Favorable safety and tolerability results support chronic... ► Artikel lesen | |
| ALUMIS | 9,900 | +1,02 % | Alumis-Aktie: No Brainer Club feiert zweistellige Kursgewinne zum Start | Gewohnt gutes Timing: Der No Brainer Club hat auch bei Alumis im richtigen Moment zugeschlagen und blickt bereits nach einem Tag auf zweistellige Kursgewinne. Nach dem massiven Abverkauf infolge enttäuschender... ► Artikel lesen | |
| IMMUNOVANT | 37,790 | -2,48 % | Immunovant, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 339,14 | -1,78 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| TARSUS PHARMACEUTICALS | 81,55 | -1,47 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved... ► Artikel lesen |